Oz Raised Concerns With PBMs, Insulin Costs, But His IRA Views Unclear

President-elect Donald Trump’s nominee for CMS administrator, Mehmet Oz, previously raised concerns with high insulin prices and the role pharmacy benefit managers play in the supply chain, but he hasn’t weighed in on the politically charged Medicare drug price negotiation process he will need to quickly take charge of if confirmed to lead the agency. As the administrator for CMS, Oz would need to take the reins on implementation of several drug price controls in Medicare as directed by the...